HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Diabetes Dialogue: 2022 Year in Review

In March 2022, together with Diana Isaacs, PharmD, and Natalie Bellini, DNP, we launched Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives.

Born to serve as a monthly podcast providing clinically applicable takeaways from the latest updates in the space, the rapid rate of advancement and news in diabetes management resulted in the creation of more than 20 episodes, including multiple special edition and on-site episodes at major meetings featuring guests and tackling historic topics, such as the approval of teplizumab. To commemorate the inaugural year and the success of Diabetes Dialogue in 2022, our editorial team has compiled a list of the 5 most popular episodes from the past year. Further in this article, we offer readers a look into each of our hosts top picks for episodes during 2022.

Diabetes Dialogue’s Top 5 of 2022

Viewers' Choices (Most Popular)

Diabetes Dialogue: Updates in Inpatient Management of Diabetes, with Jane Jeffrie Seley, DNP, MPH

In this episode of Diabetes Dialogue, Jane Jeffrie Seley, DNP, MPH, a member of the writing committee for the ADA's Standards of Care in Diabetes—2023, joins the podcast to discuss pertinent updates in the sections of the document discussing inpatient management of diabetes within the document.

Diabetes Dialogue: Optimizing CGM Uptake in Primary Care

In the first of 4 special edition episodes recorded at ADA 2022, our hosts take on the role of interviewers and discuss CGM uptake in primary care with Drs. Sean and Tamara Oser. Later in the episode, the pair provide perspective on their experiences with Beta Bionics’ Insulin-Only Bionic Pancreas.

Diabetes Dialogue: What Teplizumab Means for Type 1 Diabetes

In this special edition episode of Diabetes Dialogue, our hosts break down what the approval of teplizumab means for type 1 diabetes. During the episode, hosts take a deep dive into type 1 diabetes staging and hypothesize around the role of CDCES in educating primary care and other specialties to optimize the potential of teplizumab.

Diabetes Dialogue: Inside ADA 2022, with Diana Isaacs, PharmD, and Natalie Bellini, DNP

In their fourth and final episode from ADA 2022, our hosts take a deep dive into the meeting from their perspectives as a clinical pharmacy specialist and a nurse practitioner, including their picks for the most exciting advances in diabetes technology to come from the year’s largest diabetes meeting.

Diabetes Dialogue: The Race to Cure T1D

For the July 2022 episode of Diabetes Dialogue, host provide perspective on the latest advances in the fight to cure type 1 diabetes and offer insight into their experiences at the Practical Ways to Achieve Targets in Diabetes Care Conference held in Keystone, CO in mid-July.

Check out the preview below:


Dr. Natalie Bellini’s Top 5 Picks for 2022

Diabetes Dialogue: The Psychology of Diabetes Management, with Jill Weissberg-Benchell, PhD

In this episode of Diabetes Dialogue, Jill Weissberg-Benchell, PhD, takes hosts through her journey to becoming a diabetes care and education specialist, the role of psychologists in the management of pediatric diabetes, and her thoughts on the evolving role of care and education specialists in the management of diabetes.

Check out the preview below:

Diabetes Dialogue: The History and Future of Diabetes Technology, with Richard Bergenstal, MD

In this episode of Diabetes Dialogue, Richard Bergenstal, MD, sits down with hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss the role and evolution of technology in the management of diabetes.

Diabetes Dialogue at ADCES 22

During their time on site at ADCES 22 in Baltimore, MD, our hosts recorded 4 episodes with special guests. In this article, readers will find a collection of the on-site coverage from the annual meeting, including sit-down conversations with Korey Hood, PhD; Jennifer Clements, PharmD; Anastasia Albanese-O’Neill, PhD; and David Walton.

Diabetes Dialogue: Prescribing Tirzepatide, Biosimilar Insulins, and Misdiagnosis of T1D

In this episode, hosts discuss their experiences with prescribing tirzepatide (Mounjaro) and what issues patients have encountered, the prospect of new biosimilar insulins that may be coming to the market, and the misdiagnosis of type 1 diabetes in adult patients.

Diabetes Dialogue: December 2022

In the December 2022 episode, hosts sit down to discuss recent developments in the field, with a spotlight on the Dexcom G7 CGM, key takeaways from the ADA’s Standards of Care in Diabetes—2023, and perspective from the ADCES Diabetes Technology Conference 2022.

Check out the preview below:

Dr. Diana Isaacs Top 5 Picks for 2022

Diabetes Dialogue: Optimizing CGM Uptake in Primary Care

In the first of 4 special edition episodes recorded at ADA 2022, our hosts take on the role of interviewers and discuss CGM uptake in primary care with Drs. Sean and Tamara Oser. Later in the episode, the pair provide perspective on their experiences with Beta Bionics’ Insulin-Only Bionic Pancreas.

Diabetes Dialogue: The History and Future of Diabetes Technology, with Richard Bergenstal, MD

In this episode of Diabetes Dialogue, Richard Bergenstal, MD, sits down with hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss the role and evolution of technology in the management of diabetes.

Diabetes Dialogue: The Race to Cure T1D

For the July 2022 episode of Diabetes Dialogue, host provide perspective on the latest advances in the fight to cure type 1 diabetes and offer insight into their experiences at the Practical Ways to Achieve Targets in Diabetes Care Conference held in Keystone, CO in mid-July.

Diabetes Dialogue: Inside ADA 2022, with Diana Isaacs, PharmD, and Natalie Bellini, DNP

In their fourth and final episode from ADA 2022, our hosts take a deep dive into the meeting from their perspectives as a clinical pharmacy specialist and a nurse practitioner, including their picks for the most exciting advances in diabetes technology to come from the year’s largest diabetes meeting.

Diabetes Dialogue: What Teplizumab Means for Type 1 Diabetes

In this special edition episode of Diabetes Dialogue, our hosts break down what the approval of teplizumab means for type 1 diabetes. During the episode, hosts take a deep dive into type 1 diabetes staging and hypothesize around the role of CDCES in educating primary care and other specialties to optimize the potential of teplizumab.

Check out the preview below: